References
- Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derré A., Villéger L., Farnier M., Beucler I., Bruckert E. i wsp.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003; 34: 154–156
- Adorni M.P., Cipollari E., Favari E., Zanotti I., Zimetti F., Corsini A., Ricci C., Bernini F., Ferri N.: Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017; 256: 1–6
- An D., Wei X., Li H., Gu H., Huang T., Zhao G., Liu B., Wang W., Chen L., Ma W., Zhang H., Cao S., Yuan Z.: Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci. Rep., 2015; 5: 17559
- Arama C., Diarra I., Kouriba B., Sirois F., Fedoryak O., Thera M.A., Coulibaly D., Lyke K.E., Plowe C.V., Chrétien M., Doumbo O.K., Mbikay M.: Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS One, 2018; 13: e0192850
- Bai X.Q., Peng J., Wang M.M., Xiao J., Xiang Q., Ren Z., Wen H.Y., Jiang Z.S., Tang Z.H., Liu L.S.: PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin. Chim. Acta, 2018; 483: 192–196
- Banach M., Rizzo M., Nikolic D., Howard G., Howard V.J., Mikhailidis D.P.: Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol. Ther., 2017; 170: 181–191
- Barale C., Bonomo K., Frascaroli C., Morotti A., Guerrasio A., Cavalot F., Russo I.: Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis., 2020; 30: 282–291
- Berger J.M., Vaillant N., Le May C., Calderon C., Brégeon J., Prieur X., Hadchouel J., Loirand G., Cariou B.: PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis, 2015; 239: 252–259
- Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Hovingh G.K.: Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA, 2015; 313: 1029–1036
- Blom D.J., Djedjos C.S., Monsalvo M.L., Bridges I., Wasserman S.M., Scott R., Roth E.: Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ. Res., 2015; 117: 731–741
- Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., Ceska R., Roth E., Koren M.J., Ballantyne C.M., Monsalvo M.L., Tsirtsonis K., Kim J.B., Scott R., Wasserman S.M.: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med., 2014; 370: 1809–1819
- Boyd J.H., Fjell C.D., Russell J.A., Sirounis D., Cirstea M.S., Walley K.R.: Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J. Innate Immun., 2016; 8: 211–220
- Bułdak Ł., Marek B., Kajdaniuk D., Urbanek A., Janyga S., Bołdys A., Basiak M., Maligłówka M., Okopień B.: Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol. Pol., 2019; 70: 511–519
- Campbell J.H., Popadynec L., Nestel P.J., Campbell G.R.: Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. Atherosclerosis, 1983; 47: 279–295
- Cariou B., Benoit I., Le May C.: Preserved adrenal function in fully PCSK9-deficient subject. Int. J. Cardiol., 2014; 176: 499–500
- Cederberg H., Stančáková A., Yaluri N., Modi S., Kuusisto J., Laakso M.: Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort. Diabetologia, 2015; 58: 1109–1117
- Chang T.J., Chiu Y.F., Sheu W.H., Shih K.C., Hwu C.M., Quertermous T., Jou Y.S., Kuo S.S., Chang Y.C., Chuang L.M.: Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population. Sci. Rep., 2015; 5: 14380
- Chen S., Cao P., Dong N., Peng J., Zhang C., Wang H., Zhou T., Yang J., Zhang Y., Martelli E.E., Naga Prasad S.V., Miller R.E., Malfait A.M., Zhou Y., Wu Q.: PCSK6-mediated corin activation is essential for normal blood pressure. Nat. Med., 2015; 21: 1048–1053
- Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M., Boersma E., van Geuns R.J., Serruys P.W., Kardys I., Akkerhuis K.M.: PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS study. Atherosclerosis, 2016; 248: 117–122
- Cohen J.C., Boerwinkle E., Mosley T.H. Jr, Hobbs H.H.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006; 354: 1264–1272
- D’Ardes D., Santilli F., Guagnano M.T., Bucci M., Cipollone F.: From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood Press. Cardiovasc. Prev., 2020; 27: 1–8
- de Carvahlo L.S., Campos A.M., Sposito A.C.: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care, 2018; 41: 364–367
- Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., Seidah N.G., Prat A.: Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 2012; 125: 894–901
- Diedrich G.: How does hepatitis C virus enter cells? FEBS J., 2006; 273: 3871–3885
- Ding Z., Liu S., Wang X., Deng X., Fan Y., Shahanawaz J., Shmookler Reis R.J., Varughese K.I., Sawamura T., Mehta J.L.: Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc. Res., 2015; 107: 556–567
- Ding Z., Liu S., Wang X., Theus S., Deng X., Fan Y., Zhou S., Mehta J.L.: PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res., 2018; 114: 1145–1153
- Dyrbuś K., Gąsior M., Penson P., Ray K.K., Banach M.: Inclisiran – New hope in the management of lipid disorders? J. Clin. Lipidol., 2020; 14: 16–27
- Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C.: Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun., 2008; 374: 341–344
- Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., Corsini A., Catapano A.L.: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012; 220: 381–386
- Gencer B., Kronenberg F., Stroes E.S., Mach F.: Lipoprotein(a): The revenant. Eur. Heart J., 2017; 38: 1553–1560
- Gencer B., Mach F., Guo J., Im K., Ruzza A., Wang H., Kurtz C.E., Pedersen T.R., Keech A.C., Ott B.R., Sabatine M.S., Giugliano R.P., FOURIER Investigators: Cognition after lowering LDL-cholesterol with evolocumab. J. Am. Coll. Cardiol., 2020; 75: 2283–2293
- Geovanini G.R., Libby P.: Atherosclerosis and inflammation: Overview and updates. Clin. Sci., 2018; 132: 1243–1252
- German C.A., Shapiro M.D.: Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9. BioDrugs, 2020; 34: 1–9
- Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., Liu T., Mohanavelu S., Hoffman E.B., McDonald S.T., Abrahamsen T.E., Wasserman S.M., Scott R., Sabatine M.S., LAPLACE-TIMI 57 Investigators: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, 2012; 380: 2007–2017
- Giugliano R.P., Pedersen T.R., Saver J.L., Sever P.S., Keech A.C., Bohula E.A., Murphy S.A., Wasserman S.M., Honarpour N., Wang H., Pineda A.L., Sabatine M.S., FOURIER Investigators: Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke, 2020; 51: 1546–1554
- Guillemot J., Essalmani R., Hamelin J., Seidah N.G.: Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio, 2014; 4: 741–745
- Haas M.E., Levenson A.E., Sun X., Liao W.H., Rutkowski J.M., de Ferranti S.D., Schumacher V.A., Scherer P.E., Salant D.J., Biddinger S.B.: The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation, 2016; 134: 61–72
- Hoac B., Susan-Resiga D., Essalmani R., Marcinkiweicz E., Seidah N.G., McKee M.D.: Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone. Bone, 2018; 107: 45–55
- Hu J., Zhang Z., Shen W.J., Azhar S.: Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr. Metab., 2010; 7: 47
- Izaguirre G.: The proteolytic regulation of virus cell entry by furin and other proprotein convertases. Viruses, 2019; 11: 837
- Karagiannis A.D., Liu M., Toth P.P., Zhao S., Agrawal D.K., Libby P., Chatzizisis Y.S.: Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr. Atheroscler. Rep., 2018; 20: 20
- Khademi F., Momtazi-Borojeni A.A., Reiner Ž., Banach M., Al-Rasadi K.A., Sahebkar A.: PCSK9 and infection: A potentially useful or dangerous association? J. Cell. Pysiol., 2018; 233: 2920–2927
- Kockx M., Kritharides L.: Pancreatic PCSK9 and its involvement in diabetes. J. Thorac. Dis., 2019; 11: S2018–S2022
- Koren M.J., Scott R., Kim J.B., Knusel B., Liu T., Lei L., Bolognese M., Wasserman S.M.: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet, 2012; 380: 1995–2006
- Koskinas K.C., Windecker S., Buhayer A., Gencer B., Pedrazzini G., Mueller C., Cook S., Muller O., Matter C.M., Räber L., Heg D., Mach F.: Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clin. Cardiol., 2018; 41: 1513–1520
- Kruit J.K., Groen A.K., van Berkel T.J., Kuipers F.: Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol., 2006; 12: 6429–6439
- Kühnast S., Van Der Hoorn J.W., Pieterman E.J., van den Hoek A.M., Sasiela W.J., Gusarova V., Peyman A., Schäfer H.L., Schwahn U., Jukema J.W., Princen H.M.: Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res., 2014; 55: 2103–2112
- Labonté P., Begley S., Guévin C., Asselin M.C., Nassoury N., Mayer G., Prat A., Seidah N.G.: PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology, 2009; 50: 17–24
- Leak T.S., Keene K.L., Langefeld C.D., Gallagher C.J., Mychaleckyj J.C., Freedman B.I., Bowden D.W., Rich S.S., Sale M.M.: Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol. Genet. Metab., 2007; 92: 145–150
- Leiva E., Wehinger S.R., Guzmán L., Orrego R.: Role of oxidized LDL in atherosclerosis. W: Hypercholesterolemia, red.: S.A. Kumar. IntechOpen Limited, London 2015, 55–77
- Leritz E.C., McGlinchey R.E., Salat D.H., Milberg W.P.: Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metab. Brain Dis., 2016; 31: 465–473
- Levels J.H.M., Marquart J.A., Abraham P.R., van den Ende A.E., Molhuizen H.O.F., van Deventer S.J.H., Meijers J.C.M.: Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect. Immun., 2005; 73: 2321–2326
- Li T., Jiang S., Ni B., Cui Q., Liu Q., Zhao H.: Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. Int. J. Mol. Sci., 2019; 20: 4513
- Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R.: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020; 41: 111–188
- Małuch I., Walewska A., Sikorska E., Prahl A.: Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych. Post. Bioch., 2016; 62: 472–481
- Mannarino M.R., Sahebkar A., Bianconi V., Serban M.C., Banach M., Pirro M.: PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? J. Clin. Lipidol., 2018; 12: 1123–1132
- Mbikay M., Mayne J., Seidah N.G., Chrétien M.: Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med. Hypotheses, 2007; 69: 1010–1017
- Monami M., Sesti G., Mannucci E.: PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes. Metab., 2019; 21: 903–908
- Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B.: Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med., 2000; 108: 538–546
- Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y., Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D., DiStefano P.S., Wood A., Bingham B.: Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys., 2003; 420: 55–67
- Nishikido T., Ray K.K.: Inclisiran for the treatment of dyslipidemia. Expert Opin. Investig. Drugs, 2018; 27: 287–294
- Norata G.D., Tavori H., Pirillo A., Fazio S., Catapano A.L.: Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering. Cardiovasc. Res., 2016; 112: 429–442
- Okopień B., Bułdak Ł., Bołdys A.: Current and future trends in the lipid lowering therapy. Pharmacol. Rep., 2016; 68: 737–747
- Pasta A., Cremonini A.L., Pisciotta L., Buscaglia A., Porto I., Barra F., Ferrero S., Brunelli C., Rosa G.M.: PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin. Pharmacother., 2020; 21: 353–363
- Pavlakou P., Liberopoulos E., Dounousi E., Elisaf M.: PCSK9 in chronic kidney disease. Int. Urol. Nephrol., 2017; 49: 1015–1024
- Perego C., Da Dalt L., Pirillo A., Galli A., Catapano A.L., Norata G.D.: Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim. Biophys. Acta Mol. Basis Dis., 2019; 1865: 2149–2156
- Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem., 2008; 283: 2363–2372
- Postmus I., Trompet S., de Craen A.J., Buckley B.M., Ford I., Stott D.J., Sattar N., Slagboom P.E., Westendorp R.G., Jukema J.W.: PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J. Lipid Res., 2013; 54: 561–566
- Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., DeMicco D.A., Barter P., Cannon C.P., Sabatine M.S., Braunwald E., Kastelein J.J., de Lemos J.A., Blazing M.A., Pedersen T.R. i wsp.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA, 2011; 305: 2556–2564
- Ramanathan A., Gusarova V., Stahl N., Gurnett-Bander A., Kyratsous C.A.: Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes. PLoS One, 2016; 11: e0154498
- Ramin-Mangata S., Blanchard V., Lambert G.: Key aspects of PCSK9 inhibition beyond LDL lowering. Curr. Opin. Lipidol., 2018; 29: 453–458
- Ramos-Molina B., Martin M.G., Lindberg I.: PCSK1 variants and human obesity. Prog. Mol. Biol. Transl. Sci., 2016; 140: 47–74
- Ray K.K., Corral P., Morales E., Nicholls S.J.: Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options. Lancet, 2019; 394: 697–708
- Ricci C., Ruscica M., Camera M., Rossetti L., Macchi C., Colciago A., Zanotti I., Lupo M.G., Adorni M.P., Cicero A.F., Fogacci F., Corsini A., Ferri N.: PCSK9 induces a pro-inflammatory response in macrophages. Sci. Rep., 2018; 8: 2267
- Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr, Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Eng. J. Med., 2008; 359: 2195–2207
- Ridker P.M., Tardif J.C., Amarenco P., Duggan W., Glynn R.J., Jukema J.W., Kastelein J.J., Kim A.M., Koenig W., Nissen S., Revkin J., Rose L.M., Santos R.D., Schwartz P.F. i wsp.: Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Eng. J. Med., 2017; 376: 1517–1526
- Roth E.M., Goldberg A.C., Catapano A.L., Torri A., Yancopoulos G.D., Stahl N., Brunet A., Lecorps G., Colhoun H.M.: Antidrug antibodies in patients treated with alirocumab. N. Eng. J. Med., 2017; 376: 1589–1590
- Rouillé Y., Martin S., Steiner D.F.: Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem., 1995; 270: 26488–26496
- Ruscica M., Ricci C., Macchi C., Magni P., Cristofani R., Liu J., Corsini A., Ferri N.: Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J. Biol. Chem, 2016; 291: 3508–3519
- Sabatine M.S.: PCSK9 inhibitors: Clinical evidence and implementation. Nat. Rev. Cardiol., 2019; 16: 155–165
- Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R., FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Eng. J. Med., 2017; 376: 1713–1722
- Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., Seshasai S.R., McMurray J.J., Freeman D.J., Jukema J.W., Macfarlane P.W., Packard C.J., Stott D.J., Westendorp R.G., Shepherd J.: Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735–742
- Scamuffa N., Calvo F., Chrétien M., Seidah N.G., Khatib A.M.: Proprotein convertases: Lessons from knockouts. FASEB J., 2006; 20: 1954–1963
- Schmidt A.F., Swerdlow D.I., Holmes M.V., Patel R.S., Fairhurst-Hunter Z., Lyall D.M., Hartwig F.P., Horta B.L., Hyppönen E., Power C., Moldovan M., van Iperen E., Hovingh G.K., Demuth I., Norman K.: PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol., 2017; 5: 97–105
- Schmidt R.J., Beyer T.P., Bensch W.R., Qian Y.W., Lin A., Kowala M., Alborn W.E., Konrad R.J., Cao G.: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun., 2008; 370: 634–640
- Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., Edelberg J.M., Goodman S.G., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Mahaffey K.W., Moryusef A., Pordy R., Quintero K., Roe M.T.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Eng. J. Med., 2018; 379: 2097–2107
- Seidah N.G.: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets, 2009; 13: 19–28
- Seidah N.G.: The proprotein convertases, 20 years later. Methods Mol. Biol., 2011; 768: 23–57
- Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M.: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A., 2003; 100: 928–933
- Seidah N.G., Hamelin J., Mamarbachi M., Dong W., Tardos H., Mbikay M., Chretien M., Day R.: cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. U. S. A., 1996; 93: 3388–3393
- Seidah N.G., Prat A.: The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov., 2012; 11: 367–383
- Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.: Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J. Biol. Chem., 2012; 287: 19266–19274
- Shrestha P., van de Sluis B., Dullaart R.P.F., van den Born J.: Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell. Signal., 2019; 55: 53–64
- Steffens D., Bramlage P., Scheeff C., Kasner M., Hassanein A., Friebel J., Rauch-Kröhnert U.: PCSK9 inhibitors and cardiovascular outcomes. Expert Opin. Biol. Ther., 2020; 20: 35–47
- Stoekenbroek R.M., Lambert G., Cariou B., Hovingh G.K.: Inhibiting PCSK9 – biology beyond LDL control. Nat. Rev. Endocrinol., 2018; 15: 52–62
- Suchy D., Łabuzek K., Stadnicki A., Okopień B.: Ezetimibe – a new approach in hypercholesterolemia management. Pharmacol. Rep., 2011; 63: 1335–1348
- Syed G.H., Tang H., Khan M., Hassanein T., Liu J., Siddiqui A.: Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J. Virol., 2014; 88: 2519–2529
- Tadros H., Chrétien M., Mbikay M.: The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovary. J. Reprod. Immunol., 2001; 49: 133–152
- Tang Z.H., Peng J., Ren Z., Yang J., Li T.T., Li T.H., Wang Z., Wei D.H., Liu L.S., Zheng X.L., Jiang Z.S.: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis, 2017; 262: 113–122
- Taskinen M.R., Björnson E., Andersson L., Kahri J., Porthan K., Matikainen N., Söderlund S., Pietiläinen K., Hakkarainen A., Lund-bom N., Nilsson R., Ståhlman M., Adiels M., Parini P., Packard C.: Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjects. J. Clin. Lipidol., 2020; 14: 77–87
- Tavori H., Giunzioni I., Predazzi I.M., Plubell D., Shivinsky A., Miles J., Devay R.M., Liang H., Rashid S., Linton M.F., Fazio S.: Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc. Res., 2016, 110: 268–278
- Thomas G.: Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol., 2002; 3: 753–766
- Van Bruggen F.H., Nijhuis G.B.J., Zuidema S.U., Luijendijk H.: Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review. Expert Rev. Clin. Pharmacol., 2020; 13: 787–796
- Walley K.R., Thain K.R., Russell J.A., Reilly M.P., Meyer N.J., Ferguson J.F., Christie J.D., Nakada T.A., Fjell C.D., Thair S.A., Cirstea M.S., Boyd J.H.: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med., 2014; 6: 258ra143
- Williams D.M., Finan C., Schmidt A.F., Burgess S., Hingorani A.D.: Lipid lowering and Alzheimer disease risk: A Mendelian randomization study. Ann. Neurol., 2020, 87: 30–39
- Wu C.Y., Tang Z.H., Jiang L., Li X.F., Jiang Z.S., Liu L.S.: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol. Cell. Biochem., 2012, 359: 347–358
- Yano H., Horinaka S., Ishimitsu T.: Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J. Cardiol., 2020; 75: 289–295
- Yurtseven E., Ural D., Baysal K., Tokgözoğlu L.: An update on the role of PCSK9 in atherosclerosis. J. Atheroscler. Thromb., 2020; 27: 909–918
- Zheng-Lin B., Ortiz A.: Lipid management in chronic kidney disease: Systematic review of PCSK9 targeting. Drugs, 2018; 78: 215–229
- Zimetti F., Caffarra P., Ronda N., Favari E., Adorni M.P., Zanotti I., Bernini F., Barocco F., Spallazzi M., Galimberti D., Ricci C., Ruscica M., Corsini A., Ferri N.: Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease. J. Alzheimers Dis., 2017; 55: 315–320